• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

NOS3 Gene Record

  • Summary
  • Interactions
  • Claims
  • NOS3 4846 Druggable Genome

    Alternate Names:

    4846
    NITRIC OXIDE SYNTHASE 3
    NOS3
    ECNOS
    eNOS
    163729
    7876
    ENSG00000164867
    OTTHUMG00000158343
    P29474
    NOS3_HUMAN
    NITRIC-OXIDE SYNTHASE, ENDOTHELIAL (EC 1.14.13.39) (EC-NOS) (NOS, TYPE III) (NOSIII) (ENDOTHELIAL NOS) (ENOS) (CONSTITUTIVE NOS) (CNOS). [SOURCE:UNIPROT/SWISSPROT;ACC:P29474]
    PA254
    NITRIC OXIDE SYNTHASE, ENDOTHELIAL
    Nitric-oxide synthase endothelial
    T06046

    Gene Info:

    Target Class Enzymes
    Target Subclass EC:1.14.13.39
    Target Subclass 1.14.13.39
    Target Main Class Enzymes
    Human Readable Name DRUGGABLE GENOME
    Uniprot Status Swiss-Prot
    Uniprot Evidence 1: Evidence at protein level
    Interpro Type Domain
    Interpro Name Oxidoreductase FAD/NAD(P)-binding
    Interpro Acc IPR001433
    Interpro Short Name OxRdtase_FAD/NAD-bd
    Gene Biotype PROTEIN_CODING
    (5 More Sources)

    Gene Categories: Category Details

    DRUGGABLE GENOME

    Publications:

    Kalra S et al., 2018, Association of CYP2C19*2 and ALDH1A1*1/*2 variants with disease outcome in breast cancer patients: results of a global screening array., Eur J Clin Pharmacol
    Geng R et al., 2014, Oxidative stress-related genetic polymorphisms are associated with the prognosis of metastatic gastric cancer patients treated with epirubicin, oxaliplatin and 5-fluorouracil combination chemotherapy., PLoS One
    Choi JY et al., 2009, Nitric oxide synthase variants and disease-free survival among treated and untreated breast cancer patients in a Southwest Oncology Group clinical trial., Clin Cancer Res
    Choi HE et al., 2011, BRN-103, a novel nicotinamide derivative, inhibits VEGF-induced angiogenesis and proliferation in human umbilical vein endothelial cells., Bioorg Med Chem Lett
    Shuvalova YA et al., 2012, Association between polymorphisms of eNOS and GPx-1 genes, activity of free-radical processes and in-stent restenosis., Mol Cell Biochem
    Thorn CF et al., 2011, Doxorubicin pathways: pharmacodynamics and adverse effects., Pharmacogenet Genomics
    He H et al., 2014, Association of nitric oxide synthase 3 (NOS3) 894 G>T polymorphism with prognostic outcomes of anthracycline in Chinese patients with acute myeloid leukaemia., Clin Exp Pharmacol Physiol
    Casadei Gardini A et al., 2016, eNOS polymorphisms and clinical outcome in advanced HCC patients receiving sorafenib: final results of the ePHAS study., Oncotarget
    Venkatesan et al., 2010, Bis(morpholino-1,3,5-triazine) derivatives: potent adenosine 5'-triphosphate competitive phosphatidylinositol-3-kinase/mammalian target of rapamycin inhibitors: discovery of compound 26 (PKI-587), a highly efficacious dual inhibitor., J. Med. Chem.
    Haruna et al., 2006, Endothelial dysfunction in rat adjuvant-induced arthritis: vascular superoxide production by NAD(P)H oxidase and uncoupled endothelial nitric oxide synthase., Arthritis Rheum.
    Gautier et al., 2006, Dynamics of NO rebinding to the heme domain of NO synthase-like proteins from bacterial pathogens., Nitric Oxide
    Akamine et al., 2006, Correction of endothelial dysfunction in diabetic female rats by tetrahydrobiopterin and chronic insulin., J. Vasc. Res.
    Yang et al., 2006, L-arginine chlorination results in the formation of a nonselective nitric-oxide synthase inhibitor., J. Pharmacol. Exp. Ther.
    Ishikawa et al., Identification of arginase in human placental villi., Placenta
    Monti LD et al., 2015, Pharmacogenetic influence of eNOS gene variant on endothelial and glucose metabolism responses to L-arginine supplementation: Post hoc analysis of the L-arginine trial., Metabolism
    Mazaleuskaya LL et al., 2015, PharmGKB summary: ibuprofen pathways., Pharmacogenet Genomics
    Muniz JJ et al., 2013, Endothelial nitric oxide synthase genotypes and haplotypes modify the responses to sildenafil in patients with erectile dysfunction., Pharmacogenomics J
    Kim KM et al., 2012, Pharmacogenetics and healthcare outcomes in patients with chronic heart failure., Eur J Clin Pharmacol
    Silva PS et al., 2013, eNOS and BDKRB2 genotypes affect the antihypertensive responses to enalapril., Eur J Clin Pharmacol
    Moreno-Ulloa A et al., 2014, Cell membrane mediated (-)-epicatechin effects on upstream endothelial cell signaling: evidence for a surface receptor., Bioorg Med Chem Lett
  • ARGININE   NOS3

    Interaction Score: 19.67

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16729278 16690332 16682803 16717106 16720041 26385052


    Sources:
    PharmGKB

  • L-NAME   NOS3

    Interaction Score: 2.81

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • RONOPTERIN   NOS3

    Interaction Score: 2.81

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • SAPROPTERIN   NOS3

    Interaction Score: 1.41

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Novel drug target Established target
    Trial Name Sapropterin

    PMIDs:
    None found


    Sources:
    TdgClinicalTrial TEND

  • SILDENAFIL   NOS3

    Interaction Score: 0.8

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22064666


    Sources:
    PharmGKB

  • (-)-EPICATECHIN   NOS3

    Interaction Score: 0.51

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24794111


    Sources:
    DTC

  • SPIRONOLACTONE   NOS3

    Interaction Score: 0.3

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22543981


    Sources:
    PharmGKB

  • ENALAPRIL   NOS3

    Interaction Score: 0.28

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22706620


    Sources:
    PharmGKB

  • EPIRUBICIN   NOS3

    Interaction Score: 0.28

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25545243 19671875


    Sources:
    PharmGKB

  • CLOPIDOGREL   NOS3

    Interaction Score: 0.28

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22890915


    Sources:
    PharmGKB

  • OXALIPLATIN   NOS3

    Interaction Score: 0.23

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25545243 19671875


    Sources:
    PharmGKB

  • GEDATOLISIB   NOS3

    Interaction Score: 0.19

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    20166697


    Sources:
    DTC

  • IBUPROFEN   NOS3

    Interaction Score: 0.18

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25502615


    Sources:
    PharmGKB

  • DIGOXIN   NOS3

    Interaction Score: 0.17

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22543981


    Sources:
    PharmGKB

  • DOXORUBICIN   NOS3

    Interaction Score: 0.15

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29938344 25545243 21048526 19671875


    Sources:
    PharmGKB

  • SUNITINIB   NOS3

    Interaction Score: 0.14

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21963305


    Sources:
    DTC

  • CYCLOPHOSPHAMIDE   NOS3

    Interaction Score: 0.14

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29938344 25545243 19671875


    Sources:
    PharmGKB

  • FLUOROURACIL   NOS3

    Interaction Score: 0.11

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29938344 25545243 19671875


    Sources:
    PharmGKB

  • METHOTREXATE   NOS3

    Interaction Score: 0.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29938344 25545243 19671875


    Sources:
    PharmGKB

  • DAUNORUBICIN   NOS3

    Interaction Score: 0.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24684492


    Sources:
    PharmGKB

  • ASPIRIN   NOS3

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22890915


    Sources:
    PharmGKB

  • SORAFENIB   NOS3

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    27058899


    Sources:
    PharmGKB

  • Ensembl: ENSG00000164867

    • Version: 101_38

    Alternate Names:
    NOS3 Ensembl Gene Name

    Gene Info:
    Gene Biotype PROTEIN_CODING

    Publications:

  • RussLampel: ENSG00000164867

    • Version: 26-July-2011

    Alternate Names:
    ENSG00000164867 Ensembl Gene Id
    NOS3 Display Id
    NITRIC-OXIDE SYNTHASE, ENDOTHELIAL (EC 1.14.13.39) (EC-NOS) (NOS, TYPE III) (NOSIII) (ENDOTHELIAL NOS) (ENOS) (CONSTITUTIVE NOS) (CNOS). [SOURCE:UNIPROT/SWISSPROT;ACC:P29474] Description

    Gene Info:
    Human Readable Name DRUGGABLE GENOME

    Gene Categories:
    DRUGGABLE GENOME

    Publications:

  • TEND: P29474

    • Version: 01-August-2011

    Alternate Names:
    ENSG00000164867 Ensembl Gene Id
    P29474 Uniprot Accession
    4846 Entrez Gene Id

    Gene Info:
    Target Subclass 1.14.13.39
    Target Main Class Enzymes

    Publications:

  • TdgClinicalTrial: P29474

    • Version: January-2014

    Alternate Names:
    NOS3 Gene Symbol

    Gene Info:
    Target Class Enzymes
    Target Subclass EC:1.14.13.39

    Publications:

  • HopkinsGroom: P29474

    • Version: 11-September-2012

    Alternate Names:
    NOS3_HUMAN Uniprot Id
    ENSG00000164867 Ensembl Gene Id
    NITRIC OXIDE SYNTHASE, ENDOTHELIAL Uniprot Protein Name

    Gene Info:
    Uniprot Status Swiss-Prot
    Human Readable Name DRUGGABLE GENOME
    Uniprot Evidence 1: Evidence at protein level

    Gene Categories:
    DRUGGABLE GENOME

    Publications:

  • PharmGKB: NOS3

    • Version: 18-August-2020

    Alternate Names:
    PA254 PharmGKB ID

    Gene Info:

    Publications:
    Choi JY et al., 2009, Nitric oxide synthase variants and disease-free survival among treated and untreated breast cancer patients in a Southwest Oncology Group clinical trial., Clin Cancer Res
    Geng R et al., 2014, Oxidative stress-related genetic polymorphisms are associated with the prognosis of metastatic gastric cancer patients treated with epirubicin, oxaliplatin and 5-fluorouracil combination chemotherapy., PLoS One
    Kalra S et al., 2018, Association of CYP2C19*2 and ALDH1A1*1/*2 variants with disease outcome in breast cancer patients: results of a global screening array., Eur J Clin Pharmacol

  • DTC: NOS3

    • Version: 02-September-2020

    Alternate Names:

    Gene Info:

    Publications:
    Venkatesan et al., 2010, Bis(morpholino-1,3,5-triazine) derivatives: potent adenosine 5'-triphosphate competitive phosphatidylinositol-3-kinase/mammalian target of rapamycin inhibitors: discovery of compound 26 (PKI-587), a highly efficacious dual inhibitor., J. Med. Chem.
    Choi HE et al., 2011, BRN-103, a novel nicotinamide derivative, inhibits VEGF-induced angiogenesis and proliferation in human umbilical vein endothelial cells., Bioorg Med Chem Lett
    Moreno-Ulloa A et al., 2014, Cell membrane mediated (-)-epicatechin effects on upstream endothelial cell signaling: evidence for a surface receptor., Bioorg Med Chem Lett

  • HingoraniCasas: ENSG00000164867

    • Version: 31-May-2017

    Alternate Names:
    ENSG00000164867 Gene Symbol
    NOS3 Ensembl Id

    Gene Info:

    Gene Categories:
    DRUGGABLE GENOME

    Publications:

  • TTD: Nitric-oxide synthase endothelial

    • Version: 2020.06.01

    Alternate Names:
    NOS3 TTD Gene Abbreviation
    T06046 TTD Target ID

    Gene Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21